Researchers found an FDA-approved drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of appendix cancer. The clinical trial results show the oral medication, known as palbociclib, stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis (PMC). This form of cancer originates in the appendix and is often resistant to standard chemotherapy. "Finding that a breast cancer drug is successful in treating a subset of appendix cancer—where treatment options are currently limited—marks a significant advancement in our fight against this disease," said Andrew Lowy, MD....